Grufity logoGrufity logo

BIO

419.06USD+1.02(+0.24%)Market Closed

Bio Rad Laboratories Inc

Market Summary

USD419.06+1.02Market Closed
0.24%

BIO Alerts

BIO Stock Price

RSI Chart

Valuation

Market Cap

10.6B

Price/Earnings

-1.75

Price/Sales

3.76

Price/Cashflow

40.3

MarketCap/EBT

-1.35

Price/Sales

Profitability

EBT Margin

-279.56%

Return on Equity

-71.39%

Return on Assets

-50.05%

Fundamentals

Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

-8.86%

Revenue Q/Q

-1.49%

Earnings

Earnings (TTM)

-6.0B

Earnings Y/Y

-104.18%

Earnings Q/Q

82.29%

Price Action

52 Week Range

344.63770.76
(Low)(High)

Last 7 days

3.7%

Last 30 days

17.7%

Last 90 days

-12.4%

Trailing 12 Months

-44.0%

Financial Health

Current Ratio

5.5

Debt/Equity

0

Debt/Cashflow

46.17

Investor Care

Shares Dilution (1Y)

0.10%

Diluted EPS (TTM)

-201.8

Peers (Alternatives to Bio Rad Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
15.08% 3.58%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
3.69% -38.80%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
19.96% -3.97%
34.68
7.36
7.75% 11.02%
18.1B
2.9B
17.46% 4.00%
25.81
6.25
8.61% 6.30%
17.2B
4.6B
7.00% -22.62%
25.45
3.42
-9.73% -44.26%
MID-CAP
SMALL-CAP
2.0B
137.0M
31.93% -50.56%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
14.14% -65.84%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-6.28% -43.67%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-22.87% -81.30%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
30.54% -66.08%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-1.39% -83.46%
-19.64
2.76
31.03% -107.73%
122.6M
69.0M
6.30% -78.45%
-1.31
1.6
-18.80% -75.52%
109.5M
118.0M
6.72% -56.67%
-29.97
0.91
0.97% -269.58%
95.7M
51.6M
-0.71% -16.37%
238.75
1.86
20.72% 150.31%

Financials for Bio Rad Laboratories

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-2.3%2,8052,8712,8962,9232,980
Gross Profit-3.9%1,5741,6381,6441,6411,700
  S&GA Expenses-0.6%842847851880875
  R&D Expenses2.1%269264260272268
Earnings Before Taxes-200.5%-7,841.20-2,609.78-230.105,4388,555
Net Income-210.7%-6,034.73-1,942.46-101.184,2466,659
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-4.9%12,05812,68214,37417,77619,953
  Current Assets-3.4%3,1403,2503,3031,9892,466
    Cash Equivalents-13.2%518597802471860
  Inventory4.4%686657605572589
  Net PPE-491----
  Goodwill15.1%400347346347292
Liabilities-4.1%3,6053,7604,1914,1094,621
  Current Liabilities-7.0%571614648681650
  Long Term Debt-11----
    LT Debt, Non Current0.0%1,1971,1971,1971111
Shareholder's Equity-5.3%8,4548,92310,18313,66715,332
  Retained Earnings-1.8%9,0479,21010,13813,50715,081
  Additional Paid-In Capital-8.8%431472459442421
Accumulated Depreciation-998----
Shares Outstanding-0.5%303030--
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-46.0%262485589657783
Cashflow From Investing-0.2%-1,692.76-1,689.21-1,648.07-784.44-280.06
Cashflow From Financing0.6%1,0651,0581,182-55.43-481.95
  Buy Backs0%12512505050
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on BIO?

52.7%


Probability that Bio Rad Laboratories stock will be more than 20% underwater in next one year

28.9%


Probability that Bio Rad Laboratories stock will be more than 30% underwater in next one year.

9.6%


Probability that Bio Rad Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio Rad Laboratories was unfortunately bought at previous high price.

Returns

Cumulative Returns on BIO

14.9%


10-Year Cumulative Returns

17.1%


7-Year Cumulative Returns

9.3%


5-Year Cumulative Returns

4.1%


3-Year Cumulative Returns

What are the long-term rolling returns for BIO?

FIve years rolling returns for Bio Rad Laboratories.

Which funds bought or sold BIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
2.34
-90,000
566,000
0.02%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-1,850
13,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
12,772,000
12,772,000
0.15%
2022-11-22
CVA Family Office, LLC
SOLD OFF
-100
-7,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.88
-3,004,000
15,233,000
0.03%
2022-11-18
Legend Financial Advisors, Inc.
NEW
-
1,251
1,251
-%
2022-11-18
National Pension Service
UNCHANGED
-
-169,000
919,000
-%
2022-11-17
M&T Bank Corp
REDUCED
-15.81
381,000
1,217,000
-%
2022-11-17
CENTRAL TRUST Co
REDUCED
-3.46
-51,000
221,000
0.01%
2022-11-16
Kentucky Retirement Systems Insurance Trust Fund
ADDED
3.92
-46,000
320,000
0.03%

1–10 of 45

Latest Funds Activity

Are funds buying BIO calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BIO

Bio Rad Laboratories News

ETF Daily News

AlphaCrest Capital Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO).11 hours ago

BIO Fair Value

Recent SEC filings of Bio Rad Laboratories

View All Filings
Date Filed Form Type Document
Nov 28, 2022
4
Insider Trading
Nov 21, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 08, 2022
8-K
Current Report
Oct 28, 2022
10-Q
Quarterly Report
Oct 27, 2022
8-K
Current Report
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Norman D. Schwartz
7900
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Income Statement

2022-09-30
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net sales$ 680,800$ 747,049$ 2,071,961$ 2,189,776
Cost of goods sold307,008309,614898,628950,116
Gross profit373,792437,4351,173,3331,239,660
Selling, general and administrative expense211,047216,150617,371655,428
Research and Development Expense69,94964,481199,526201,784
Segment profit (loss)92,796156,804356,436382,448
Interest expense11,66342626,4311,187
Foreign exchange (gains) losses, net4,3642,2323,133542
Marketable Securities, Unrealized (Gain) Loss288,999(4,868,659)6,172,306(7,078,753)
Other Nonoperating Income (Expense)3,062(579)42,36916,732
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest(209,168)5,022,226(5,803,065)7,476,204
(Provision) benefit for income taxes44,936(1,094,193)1,342,036(1,656,643)
Net income attributable to Bio-Rad$ (164,232)$ 3,928,033$ (4,461,029)$ 5,819,561
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad$ (5.52)$ 131.75$ (149.60)$ 195.29
Weighted average common shares - basic29,73329,81429,81929,800
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad$ (5.52)$ 129.96$ (149.60)$ 192.76
Weighted average common shares - diluted29,73330,22429,81930,190

BIO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
ASSETS:  
Cash and cash equivalents$ 517,943$ 470,783
Short-term investments1,332,180399,135
Restricted investments5,5605,560
Accounts receivable, net432,302423,537
Inventories:  
Total inventories685,850572,239
Prepaid expenses147,198107,745
Other current assets19,12210,089
Total current assets3,140,1551,989,088
Property, plant, and equipment1,481,6581,488,568
Less: accumulated depreciation and amortization1,020,546997,616
Property, plant and equipment, net461,112490,952
Operating lease right-of-use assets171,587204,798
Goodwill, net399,589347,343
Purchased intangibles, net325,076253,939
Other investments7,459,16914,387,006
Other assets101,774102,669
Assets12,058,46217,775,795
LIABILITIES AND STOCKHOLDERS' EQUITY:  
Accounts payable142,746141,941
Accrued payroll and employee benefits192,460276,986
Current maturities of long-term debt and notes payable448489
Income and other taxes payable29,27446,299
Current operating lease liabilities34,04336,435
Other current liabilities171,706178,788
Total current liabilities570,677680,938
Long-term debt, net of current maturities1,197,27210,514
Deferred income taxes1,484,6063,059,080
Operating lease liabilities147,211175,938
Other long-term liabilities205,091182,191
Total liabilities3,604,8574,108,661
Stockholders' equity:  
Additional paid-in capital430,547441,733
Retained earnings9,046,53013,507,241
Accumulated other comprehensive loss(845,214)(175,553)
Total stockholders' equity8,453,60513,667,134
Total liabilities and stockholders' equity12,058,46217,775,795
Common Class A [Member]  
Stockholders' equity:  
Common stock22
Common Class B [Member]  
Stockholders' equity:  
Common stock11
Treasury Class A [Member]  
Stockholders' equity:  
Treasury stock$ (178,261)$ (106,290)
Treasury Stock [Member]  
Stockholders' equity:  
Treasury Stock, Shares412,075412,075